Clinical trials: Diabetes Type 2
Metabolic Syndrome
Mechanisms of Ramipril Reduction in the Onset of Type 2 Diabetes
The study will be focused on determining the integrated in-vivo mechanisms responsible for Ramipril's effects on delaying type 2 diabetes and restoring normal (blood sugar levels) glycemia in patients with impaired glucose…
- Trial name
- NCT00574834
- Testing
- Ramipril, HCTZ-hydrochlorothiazide, Ramipril+HCTZ
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Type 2 Diabetes, Homeless Persons
Diabetes Homeless Medication Support Single Arm Treatment Development Trial
This single-arm trial of the Diabetes Homeless Medication Support intervention alone (n=15) will test the perception and feasibility of anticipated study procedures.
- Trial name
- D-Homes (NCT04678284)
- Testing
- Diabetes Homeless Medication Support (D-Homes)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Hennepin Healthcare Research Institute
Type 2 Diabetes Mellitus
A Study to Characterize Regimens of Basal Insulin Intensified With Either Symlin® or Rapid Acting Insulin in Patients With Type 2 Diabetes
This will be a randomized, open label, parallel group, multicenter study. There will be two phases in the study. Phase 1 (Baseline to Week 24) will compare the efficacy and safety of regimens of basal insulin intensified with…
- Trial name
- NCT00467649
- Testing
- pramlintide acetate (Symlin), rapid acting insulin (Humalog® [insulin lispro], Novolog® [insulin aspart], or Apidra® [insulin glulisine]), basal insulin (Lantus® [insulin glargine], or Levemir® [insulin detemir])
- Where
- 37 sites in United States
- Volunteers
- 112 people
- Sponsor
- AstraZeneca
Type2 Diabetes, High Blood Sugar
Evaluate Safety as Mono or Combination Therapies With Anti-diabetes Mellitus Drugs in Japanese Subjects With Type 2 Diabetes Mellitus
This is a long term, single arm, open label study to evaluate the safety and efficacy of dapagliflozin as monotherapy or in combination therapy with other anti diabetic drug in Japanese subjects with type 2 diabetes mellitus who…
- Trial name
- NCT01294436
- Testing
- Dapagliflozin
- Where
- 38 sites in Japan
- Volunteers
- 728 people
- Sponsor
- AstraZeneca
Diabetes, Diabetes Mellitus, Type 2
Comparison of NN5401 With Insulin Glargine in Insulin Naive Subjects With Type 2 Diabetes
This trial is conducted in Japan. The aim of this trial is to investigate the efficacy and safety of NN5401 (insulin degludec/insulin aspart) with insulin glargine in subjects with type 2 diabetes in Japan.
- Trial name
- BOOST™ (NCT01272193)
- Testing
- insulin degludec/insulin aspart, insulin glargine
- Where
- 50 sites in Japan
- Volunteers
- 296 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
A New Oral Treatment For Type II Diabetes Mellitus
This is a 24-week study investigating the safety and efficacy of several dosages of a potential new oral medicine for Type II diabetes mellitus.
- Trial name
- NCT00111800
- Testing
- DEN 2.5 mg, DEN 7.5 mg, DEN 15 mg
- Where
- 109 sites in United States, Canada and 8 more
- Volunteers
- 375 people
- Sponsor
- GlaxoSmithKline
Diabetes, Diabetes Mellitus, Type 2
Comparison of Biphasic Insulin Aspart 30 Versus Insulin Glargine Both in Combination With Metformin and Glimepiride in Subjects With Type 2 Diabetes
This trial is conducted in Africa, Asia, Europe, Oceania and South America. This trial aims for a comparison of biphasic insulin aspart 30 once daily versus insulin glargine once daily all in combination with metformin and…
- Trial name
- NCT00469092
- Testing
- biphasic insulin aspart, insulin glargine, metformin
- Where
- 69 sites in Argentina, Austria and 13 more
- Volunteers
- 480 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
Comparison of the Change in Fat Distribution in Overweight and Obese Subjects With Type 2 Diabetes After Insulin Treatment
This trial is conducted in Europe. The aim of this clinical trial is to compare the change in trunk fat mass, assessed by Double Energy X-ray Absorptiometry (DEXA) after 26 weeks of treatment with insulin detemir or insulin NPH…
- Trial name
- NCT00795600
- Testing
- insulin detemir, insulin NPH
- Where
- Spain
- Volunteers
- 60 people
- Sponsor
- Novo Nordisk A/S
NASH - Nonalcoholic Steatohepatitis, Diabetes Mellitus, Type 2
Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus
The study in the T2DM population is intended to confirm the lanifibranor effect versus placebo on glycemic control and assess a positive effect of the combination of lanifibranor with an SGLT2 inhibitor on glycemic control.
- Trial name
- LEGEND (NCT05232071)
- Testing
- Lanifibranor, Empagliflozin
- Where
- 42 sites in United States, Belgium and 3 more
- Volunteers
- 39 people
- Sponsor
- Inventiva Pharma
Type 2 Diabetes
Sitagliptin Dose Comparison Study in Patients With Type 2 Diabetes (MK-0431-077)(COMPLETED)
A study to assess the safety and efficacy of sitagliptin 100mg compared to sitagliptin 200mg in patients with type 2 diabetes.
- Trial name
- NCT00541229
- Testing
- sitagliptin phosphate
- Volunteers
- 103 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2
Study Of GW823093 In Japanese Subjects With Type 2 Diabetes Mellitus
To investigate the preliminary pharmacokinetics, pharmacodynamics, safety and tolerability of GW823093 at doses of 15mg and 30mg given once daily for 7 days in Japanese Type 2 diabetes mellitus (T2DM) patients.
- Trial name
- NCT00372957
- Testing
- GW823093 15mg, GW823093 30mg
- Volunteers
- 30 people
- Sponsor
- GlaxoSmithKline
Diabetes Mellitus, Postprandial Lipemia
Effects of Sitagliptin on Postprandial Lipemia in Men With Type 2 Diabetes
Sitagliptin is a potent and selective inhibitor of dipeptidyl peptidase IV (DPP-4), and has been shown to reduce fasting and postprandial glucose levels in patients with type 2 diabetes mainly through incretin hormone-mediated…
- Trial name
- NCT00660075
- Testing
- Sitagliptin
- Where
- Canada
- Volunteers
- 36 people
- Sponsor
- Laval University
Type 2 Diabetes Mellitus
VERIFY:A Study to Compare Combination Regimen With Vildagliptin & Metformin Versus Metformin in Treatment-naïve Patients With Type 2 Diabetes Mellitus
The purpose of this study was to determine whether the initiation of a vildagliptin plus metformin combination regimen would result in more durable glycemic control than metformin monotherapy in treatment-naïve patients with…
- Trial name
- NCT01528254
- Testing
- vildagliptin, Metformin
- Where
- 227 sites in Argentina, Australia and 32 more
- Volunteers
- 2,004 people
- Sponsor
- Novartis Pharmaceuticals
Diabetes Mellitus, Type 2
Efficacy and Safety of Toujeo® Versus Tresiba® in Insulin-Naive Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Oral Antihyperglycemic Drug(s) ± GLP-1 Receptor Agonist
Primary Objective: To demonstrate the noninferiority in the efficacy of Toujeo® to Tresiba® in glycated hemoglobin (HbA1c) change from Baseline to Week 24.
- Trial name
- BRIGHT (NCT02738151)
- Testing
- Insulin glargine, 300U/mL, Insulin degludec, 100 U/mL, Non-insulin anti-diabetic treatment
- Where
- 158 sites in United States, Bulgaria and 14 more
- Volunteers
- 929 people
- Sponsor
- Sanofi
Type 2 Diabetes Mellitus
Effects and Safety of OPK-88003 Dose Escalation in Type 2 Diabetes Subjects
This study will evaluate the effect of dose escalation of once-weekly (QW) subcutaneous (SC) OPK-8003 injections vs placebo on HbA1c absolute change from baseline at 30 weeks in subjects with type 2 diabetes mellitus (T2DM)…
- Trial name
- NCT03406377
- Testing
- OPK-88003
- Where
- 3 sites in United States
- Volunteers
- 113 people
- Sponsor
- OPKO Health, Inc.
Type2 Diabetes, Cardiovascular Diseases
Dapagliflozin and Measures of Cardiovascular Autonomic Function in Patients With Type 2 Diabetes (T2D)
The purpose of this study is to evaluate the effect of dapagliflozin, a FDA approved diabetes medication, on measures of nervous system function of the heart in patients with type 2 diabetes.
- Trial name
- NCT02973477
- Testing
- Dapagliflozin, Glimepiride
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- University of Michigan
Nonalcoholic Fatty Liver Disease (NAFLD), Type 2 Diabetes (T2DM)
Lanifibranor in Patients With Type 2 Diabetes & Nonalcoholic Fatty Liver Disease
The primary aim is to establish the safety, efficacy and mechanism of action of lanifibranor in patients with type 2 diabetes (T2DM) and nonalcoholic fatty liver disease (NAFLD).
- Trial name
- NCT03459079
- Testing
- Lanifibranor
- Where
- United States
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- University of Florida
Type 1 Diabetes Mellitus, Hypoglycemia
24/7 Closed-loop in Older Subjects With Type 1 Diabetes
The main objective of this open-label, multi-centre, randomised, crossover design study is to determine whether automated day and night closed-loop insulin delivery for 16 weeks under free living conditions is safer and more…
- Conditions
- Type 1 Diabetes Mellitus, Hypoglycemia, Arrythmia
- Trial name
- DAN06 (NCT04025762)
- Testing
- Hybrid closed-loop system (CamAPS FX), Sensor augmented pump therapy
- Where
- 2 sites in United Kingdom
- Volunteers
- 38 people
- Sponsor
- University of Cambridge
Type 2 Diabetes Mellitus
Specified Drug-Use Survey of Trelagliptin Tablets "Survey on Long-term Use in Type 2 Diabetes Mellitus Patients With Severe Renal Impairment or End-stage Renal Disease"
The purpose of this study is to evaluate the long-term safety of trelagliptin tablets in patients with type 2 diabetes mellitus complicated by severe renal impairment or end-stage renal failure in the routine clinical setting.
- Trial name
- NCT04285983
- Testing
- Trelagliptin
- Where
- Japan
- Volunteers
- 89 people
- Sponsor
- Takeda
Diabetes, Weightloss
The WISE (Weightloss Intervention Surgical Effects) Brain Study
This study is being done to learn about the changes that weight loss causes on brain function, memory and thinking ability in adults. The study does NOT cover any costs associated with bariatric surgery.
- Trial name
- WISEBrain (NCT02137070)
- Testing
- Bariatric Surgery Candidates, Non surgical/Community volunteers
- Where
- United States
- Volunteers
- 197 people, healthy volunteers welcome
- Sponsor
- University of Florida